Effect of Ileocolic-released Conjugated Bile Acid on Satiety, Entero-Endocrine Cell Function, and Body Weight in Patients With Obesity and Abnormal Satiety Phenotype
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 35
- 试验地点
- 1
- 主要终点
- Glucagon-Like Peptide-1 (GLP-1)
研究概览
简要总结
The purpose of this research is to study the effect of the study drug (a conjugated bile acid dietary supplement) or placebo on cell function, hormones and body weight.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Bile Acid Supplement Group
Subjects with obesity and abnormal satiety phenotype will receive ileocolonic-release conjugated bile acid supplements
干预措施: Ileocolonic-release conjugated bile acid (Dietary Supplement)
Placebo Group
Subjects with obesity and abnormal satiety phenotype will receive matching-placebo
干预措施: Placebo (Drug)
结局指标
主要结局
Glucagon-Like Peptide-1 (GLP-1)
时间窗: 90 days
The number of participants that provided a blood sample for GLP-1 (ug/ml) .
Peptide Trosin Tyrosine (PYY) Hormone
时间窗: 90 days
The number of participants that provided a blood sample for PYY.
次要结局
- Change in Weight(Baseline, 12 weeks)
研究者
Andres J. Acosta, M.D., Ph.D.
Principal Investigator
Mayo Clinic
